Vorinostat for Rett syndrome safety study
Treatments studied
Part of Brain & nervous system, Genetic & congenital clinical trials.
This trial tests whether vorinostat is safe and helpful for girls and young women with Rett syndrome. Participants must have a confirmed MeCP2 mutation and be in a stable phase of the condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Female aged 6 to 21 years
- Diagnosed with typical Rett syndrome with a confirmed MeCP2 mutation
- No worsening of walking, hand use, talking, or communication in the past 4 months
- Stable medications (including seizure meds) for at least 4 weeks before starting; if taking trofinetide, stable for 6 months
- Able to swallow capsules or take them through a feeding tube
- Willing to wear a small activity monitor on wrist or ankle
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral medication called NA-921 in females with Rett syndrome to see if it works better than a placebo. It may be an option for those who have a confirmed MECP2 gene mutation and stable seizure patterns.
This trial tests a new study drug called NTI164 to see if it can safely help manage Rett syndrome symptoms in girls and young women. It is for those with classic Rett syndrome who have been stable recently and are not using certain other treatments.
This Phase 2 trial studies whether an antioxidant “cocktail” helps children and teens with Rett syndrome compared with a placebo (inactive drink). If you join, you’ll get study assessments and blood tests to see if the treatment is safe and helpful.
This study tests whether lamivudine, a medication originally used for HIV, might help improve symptoms in people with Rett syndrome. Researchers will monitor how safe and effective the treatment is over time.
This study tests whether fenfluramine, a medication already used for seizures, can help people with Rett syndrome. It aims to see if it improves daily life and reduces symptoms.
This study looks at how trofinetide (a medicine for Rett syndrome) affects thinking and memory in people with Rett syndrome. It will follow participants who are starting this treatment through a specific clinic.
Hear when a new Rett Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.